In patients with chronic refractory angina (Canadian Cardiovascular Society class III‑IV) who are not candidates for percutaneous coronary intervention or coronary artery bypass grafting, what are the indications, contraindications, implantation technique, and post‑procedure antiplatelet regimen for a coronary sinus reducer?

Coronary Sinus Reducer for Chronic Refractory Angina

The coronary sinus reducer (CSR) is indicated for patients with Canadian Cardiovascular Society (CCS) class III-IV refractory angina who have exhausted revascularization options and remain symptomatic despite maximal medical therapy, with demonstrated myocardial ischemia on objective testing. 1, 2

Patient Selection Criteria

Indications

• Angina severity: CCS class III or IV symptoms despite optimal medical therapy (≥2 antianginal medications, ideally ≥3) 1, 2
• Revascularization status: Not candidates for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), or have exhausted these options 1, 3
• Objective ischemia: Documented myocardial ischemia on non-invasive testing (stress echo, perfusion imaging, or exercise testing) 1, 2
• Preserved left ventricular function: Most patients (74%) have LVEF ≥50%, though not an absolute requirement 2

Contraindications

• Acute coronary syndrome or unstable angina requiring urgent revascularization
• Significant left main disease amenable to CABG 4
• Coronary anatomy suitable for revascularization with acceptable risk
• Severe right heart failure or elevated right atrial pressure
• Anatomical barriers: severe coronary sinus stenosis, unfavorable venous anatomy, or inability to access coronary sinus 5

Critical caveat: The device appears particularly effective in patients with microvascular dysfunction rather than purely macrovascular disease, with nonresponder rates of 15-30% 6. Consider invasive coronary function testing when available to identify microvascular impairment before CSR implantation 7.

Implantation Technique

Procedural Approach

The CSR is a balloon-expandable, stainless steel, hourglass-shaped device that creates focal narrowing in the coronary sinus 1:

• Venous access: Right internal jugular vein is preferred for optimal coronary sinus alignment, though femoral access is acceptable 5
• Delivery system: 12 French delivery sheath advanced into coronary sinus
• Device positioning: Deploy in mid-to-distal coronary sinus to create controlled outflow obstruction
• Deployment technique: Balloon expansion to create hourglass configuration

Technical Considerations

• Anatomical challenges: Prominent Thebesian valve may impede sheath advancement; balloon-assisted tracking can facilitate passage 5
• Pre-existing cardiac devices: CSR can be safely implanted in patients with existing left ventricular pacing leads using careful technique, selective venography, and monitoring of pacing parameters 5
• Procedural success rate: 95% in real-world practice 2

Safety Profile

• Periprocedural adverse events: 9.2% overall, predominantly access site complications 2
• Major adverse cardiovascular events: <1% 2
• Hospital stay: 98% of patients discharged within 1 night 2

Post-Procedure Antiplatelet Regimen

The evidence does not provide specific antiplatelet recommendations for CSR implantation. However, applying principles from coronary device implantation 8, 9:

Recommended Regimen

• Aspirin 75-100 mg daily indefinitely (extrapolated from general coronary device management) 8, 9
• Clopidogrel 75 mg daily for 1-3 months post-implantation (reasonable based on venous stent principles)
• Long-term: Aspirin monotherapy after initial dual antiplatelet period

Important note: Unlike coronary artery stenting, CSR is a venous device with lower thrombotic risk. The optimal antiplatelet duration remains undefined in published guidelines, but shorter dual therapy (1-3 months) followed by aspirin alone represents a reasonable approach based on device location and thrombotic risk profile.

Expected Outcomes

Efficacy at 6 Months

The COSIRA trial and UK national audit demonstrate 1, 2:

• ≥2 CCS class improvement: 35-36% of patients
• ≥1 CCS class improvement: 71-75% of patients
• Quality of life: Significant improvement (17.6 vs 7.6 points on Seattle Angina Questionnaire, P=0.03) 1

Responder Characteristics

CSR appears most effective in patients with:

• Microvascular dysfunction or angina with no obstructive coronary artery disease (ANOCA) 6, 7
• Preserved left ventricular function 2
• Documented ischemia on objective testing 1

Clinical Context

The 2024 ESC guidelines recognize alternative therapies for refractory angina but emphasize that evidence remains limited 10. Older guidelines 11, 12 mention spinal cord stimulation, enhanced external counterpulsation, and transmyocardial revascularization only for patients who cannot be managed with medical therapy and are not revascularization candidates.

CSR represents the only guideline-recommended percutaneous treatment for refractory angina 2, 3, with stronger evidence than historical alternatives. The device should be considered after:

1. Optimization of medical therapy (beta-blockers, calcium channel blockers, long-acting nitrates, ranolazine, ivabradine, trimetazidine as appropriate) 10
2. Confirmation that no further revascularization options exist 4, 13, 14
3. Documentation of objective ischemia 1

Common pitfall: Do not implant CSR in patients who remain revascularization candidates or who lack objective evidence of ischemia. The 15-30% nonresponder rate 6 suggests careful patient selection is critical for optimal outcomes.